弥漫大B细胞淋巴瘤早期化疗免疫治疗失败的特征与预测模型(表1)

弥漫大B细胞淋巴瘤早期化疗免疫治疗失败的临床特征与预测模型数据集,含2038例患者的多项临床和基因数据。

NIAID Data Ecosystem
浏览 17
表格DLBCL - diffuse large B cell lymphomaearly chemoimmunotherapy failureRCHOP-like regimenCAR- T cellschemo-resistantnomogram
Table 1: Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure

基本信息

模态
表格
大小
0.000031901 GB
许可
CC BY 4.0
创建/更新时间
2026-10-08
版本
v1

资源简介

弥漫大B细胞淋巴瘤早期化疗免疫治疗失败的特征与预测模型(表1)

【一句话概览】

本数据集是 figshare 公开的结构化表格数据集,收录 1 个文件、合计 31.90 KB,主题涵盖 DLBCL - diffuse large B cell lymphoma、early chemoimmunotherapy failure、RCHOP-like regimen、CAR- T cells、chemo-resistant,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。

【数据集背景】

本数据集源站标题为《Table 1_Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.docx》。配套论文《Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma》发表于 British Journal of Haematology(2021),DOI:10.1111/bjh.17858。源站首次发布:2025-06-16。

【数据内容】

源站原始描述:IntroductionThe outcomes of refractory or relapsed diffuse large B-cell lymphoma are generally poor, especially those relapsed or progressed within 12 months from diagnosis named as early chemoimmunotherapy failure (ECF), with a 2-year OS of 24.7%. Due to the dismal outcome, early recognition of ECF and developing targeted innovative treatments to improve patient prognosis are urgent. MethodsThis study recruited 2038 newly diagnosed DLBCL patients treated with R-CHOP/RminiCHOP or R-CHOP-based im…

【数据结构与技术规格】

文件数 1 个,合计 31.90 KB。Table 1_Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,31.90 KB。数据集 DOI:10.3389/fimmu.2025.1553850.s007。

【主题与分类】

源站学科分类:Genetic Immunology。主题标签:DLBCL - diffuse large B cell lymphoma、early chemoimmunotherapy failure、RCHOP-like regimen、CAR- T cells、chemo-resistant、nomogram。

【适用方向】

结构化表格数据可直接用于统计建模、特征工程与队列分析。

【获取与许可】

源站页面:https://frontiersin.figshare.com/articles/dataset/Table_1_Characteristics_and_predictive_model_for_diffuse_large_B-cell_lymphoma_with_early_chemoimmunotherapy_failure_docx/29324846

使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。

规范引用:Dong, Ying-Yu; Shi, Qing; Wu, Wen; Zhao, Bing-Bing; Fu, Di; Xu, Peng-Peng; et al. (2025). Table 1_Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.docx. Frontiers. Dataset

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付,我们提供全链路闭环服务,让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持?联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。

免登录

有偿下载

公开数据集受托下载与技术交付服务。

提供高速下载与技术交付服务(收技术服务费,非数据销售)

暂未开放

当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。

使用方式

数据集获取(Figshare)

命令行下载

curl -L -o "Table 1_Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.docx" "https://ndownloader.figshare.com/files/55401320"

文件清单

  • Table 1_Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.docx(31.90 KB)

文件总体积 31.90 KB(源站 API 实测)。

数据加载示例(图像类)

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

IntroductionThe outcomes of refractory or relapsed diffuse large B-cell lymphoma are generally poor, especially those relapsed or progressed within 12 months from diagnosis named as early chemoimmunotherapy failure (ECF), with a 2-year OS of 24.7%. Due to the dismal outcome, early recognition of ECF and developing targeted innovative treatments to improve patient prognosis are urgent.
MethodsThis study recruited 2038 newly diagnosed DLBCL patients treated with R-CHOP/RminiCHOP or R-CHOP-based immunochemotherapy in Ruijin hospital and 411 hospital from December 1997 to December 2020.
ResultsCompared to the control group, ECF patients were significantly associated with elderly age, advanced Ann Arbor stage, elevated serum LDH, poor performance status, multiple extranodal involvements, double expressor lymphoma (DEL), and non-GCB subtype, as well as high frequencies of TP53, FOXO1 and FBXW7 mutations. Through multivariate analysis, elderly age, advanced stage, elevated serum LDH, DEL, and mutations of TP53 or FOXO1 were independent predictors of ECF.
DiscussionBased on these predictors, a nomogram of ECF was established, and the straining cohort of our Chinese patients as well as the external cohort from Western countries showed a good predictive power of the ECF model, indicating the efficiency of our ECF predicting model, regardless of patients’’ race. Our ECF model allows clinicians to early recognize ECF patients, to optimize the therapeutic strategies and to improve the outcome of those chemo-resistant patients.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2025.1553850.s007(source: https://frontiersin.figshare.com/articles/dataset/Table_1_Characteristics_and_predictive_model_for_diffuse_large_B-cell_lymphoma_with_early_chemoimmunotherapy_failure_docx/29324846)。

数据缺失?

依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。

⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。

获取专属数据定制方案